Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Puma Biotechnology, Inc. (PBYI : NSDQ)

• Company Description    Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also approved in the European Union. Nerlynx in combination with Roche's Xeloda was approved?by the Food and Drug Administration for third-line HER2-positive metastatic breast cancer. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations as well as other types of cancers are currently underway. A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers. Puma markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets. Number of Employees: 172

• Price / Volume Information    Yesterday's Closing Price: $5.95 Daily Weekly Monthly 20 Day Moving Average: 338,601 shares Shares Outstanding: 50.39 (millions) Market Capitalization: $299.83 (millions) Beta: 1.19 52 Week High: $6.27 52 Week Low: $2.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.48% 12.67% 12 Week 14.20% 12.36% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10880 WILSHIRE BOULEVARD SUITE 2150 - LOS ANGELES,CA 90024 USA ph: 424-248-6500 fax: 424-248-6501 ir@pumabiotechnology.com http://www.pumabiotechnology.com

• General Corporate Information    Officers Alan H. Auerbach - President & Chief Executive Officer Maximo Nougues - Principal Financial Officer and Principal Accounti Alessandra Cesano - Director Allison Dorval - Director Michael P. Miller - Director Peer Information Puma Biotechnology, Inc. (CORR.) Puma Biotechnology, Inc. (RSPI) Puma Biotechnology, Inc. (CGXP) Puma Biotechnology, Inc. (BGEN) Puma Biotechnology, Inc. (GTBP) Puma Biotechnology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74587V107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 50.39 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $299.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.31 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: 19.19 Trailing 12 Months: 8.04 PEG Ratio: - Price Ratios Price/Book: 2.60 Price/Cash Flow: 6.98 Price / Sales: 1.41 EPS Growth vs. Year Ago Period: -58.54% vs. Previous Quarter: 41.67% Sales Growth vs. Year Ago Period: -32.30% vs. Previous Quarter: 4.01% ROE 12/31/25 - - 09/30/25 - 36.17 06/30/25 - 53.15 ROA 12/31/25 - - 09/30/25 - 18.33 06/30/25 - 23.51 Current Ratio 12/31/25 - - 09/30/25 - 1.74 06/30/25 - 1.73 Quick Ratio 12/31/25 - - 09/30/25 - 1.62 06/30/25 - 1.62 Operating Margin 12/31/25 - - 09/30/25 - 17.45 06/30/25 - 20.38 Net Margin 12/31/25 - - 09/30/25 - 17.45 06/30/25 - 20.38 Pre-Tax Margin 12/31/25 - - 09/30/25 - 14.58 06/30/25 - 17.76 Book Value 12/31/25 - - 09/30/25 - 2.29 06/30/25 - 2.11 Inventory Turnover 12/31/25 - - 09/30/25 - 5.51 06/30/25 - 9.17 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.10 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 9.40

Powered by Zacks Investment Research ©